Innovative MODels Initiative (IMODI)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: Oncodesign
  • Initiator Type: Third-party organization
  • Disease focus:
  • Location: Europe


The Innovative MODels Initiative (IMODI) aims to facilitate the selection of new and effective treatments against cancer diseases. This French initiative aims to pool the resources allocated to the development and characterization of more than 200 experimental models predictive of cancer, a wide range of organic products and derivatives selection tests molecules. The project also includes the establishment of a centralized biobank of more than 40,000 biological samples and powerful analysis dedicated to the identification of tumor biomarkers from immunological and microbiome data.


IMODI’s aim is to pool the resources allocated to the development and the profiling of predictive experimental cancer models in eight cancer pathologies and a wide range of derivative biological products and tests for compound selection. IMODI also plans to create a centralized biobank and powerful data analysis tools designed to identify tumor and immunological biomarkers, as well as those coming from the gut microbiome.

Consortium History

2013: IMODI began with an expected duration of 84 months.


The global budget is €41.0 million of which €13.4 million is public funding.

Other website

Points of Contact

Project Leader
Olivier Duchamp
Director Scientific Partnerships and Technology Transfer
20, rue Jean Mazen BP 27627
21076 DIJON Cedex
phone: +33 (0)3 80 78 82 60

Sponsors & Partners

Ariana Pharma


Centre Georges Francois Leclerc de Dijon

Centre Leon Berard

CHU de Toulouse

CTI Biotech






Pierre Fabre centre immunologie



Synergie Lyon cancer

Universite de Strasbourg

Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.